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database would not be outdated prior to the end of the study, it 
was necessary to incorporate state-of-the-art MR systems and 
acquisition pulse sequences into the study. Use of 3 Tesla (3T) 
MR systems were selected for the study and several pilot investi- 
gations were undertaken to identify appropriate acquisition proto- 
cols and to cross-validate the quantitative MR measurements to 
those validated irectly. 
The first pilot study, conducted at Ohio State University (OSU), 
had as a goal to help select the optimal acquisition, including 
planes, parameters and pulse sequences for the OAI. MR images 
were obtained in thirteen knees at 3T using sixteen different ac- 
quisitions. These initial MR acquisitions were selected by the OAI 
Imaging Committee after several rounds of protocol optimization 
had been performed. 
Nine 3D series, including two multi-planar eformats (MPRs), 
were evaluated for suitability for cartilage segmentation by five 
persons from cartilage segmentation teams. Nine 2D series, in- 
cluding two multi-slice multi-echo (MSME) T2 map acquisitions, 
were evaluated by six musculoskeletal radiologists for suitabil- 
ity to assess joint structural integrity as well as for discrimi- 
nation of cartilage defects, bone marrow edema-like (BME) le- 
sions and bone cysts. Evaluation criteria included cartilage con- 
trast/structure discrimination relative to surrounding tissues, pres- 
ence/extent of image artifacts, anatomic coverage, fat suppres- 
sion uniformity, and signal uniformity. 
A second pilot study for the OAI, conducted at OSU and Memorial 
Hospital of Rhode Island (MHRI), acquired test-retest MR images 
in the knees of 19 subjects with no to moderate degrees of clin- 
ical OA. Two studies with double oblique coronal 3D FLASH se- 
quences with water excitation (WE) and 1.5mm slice thickness 
were acquired at 3T. In addition, two studies with sagittal 3D 
DESS WE sequences with 0.7mm slice thickness were also ac- 
quired. From the sagittal 3D DESS acquisitions, double oblique 
coronal multi-planar reformats (MPR) were performed at 1.5mm 
slice thickness. 
Knee cartilage volume, surface area, thickness and subcortical 
bone surface area were quantified by four analysis teams in an 
unpaired manner from the 114 image series. Subject identifica- 
tion, image pairs and series were blinded. Regions of interest 
and segmentation rules were determined by concensus of all four 
teams prior to distribution of the blinded images. 
The MR imaging protocol which resulted from the initial pilot study 
will be presented. In addition, a summary of the range of individ- 
ual team results as well as the meta-analysis of the segmentation 
results from the second pilot study will be presented along with a 
description of the subject cohort. A synopsis of the ongoing MR 
pilot studies will also be presented. 
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OA BIOMARKERS: THE CLINICAL TRIAL PERSPECTIVE. 
RADIOGRAPHY 
Marie-Pierre Hellio Le Graverand 
Conventional radiography is the simplest and least expensive 
method for imaging joints in osteoarthritis (OA). Radiographs 
clearly visualize bony features including marginal osteophytes, 
subchondral sclerosis and subchondral cysts that are associated 
with OA but provide only an estimate of cartilage thickness by 
the interbone distance or joint space width (JSW). Radiography 
is used in clinical practice to establish the diagnosis and to moni- 
tor the progression of OA. Various radiographic definitions of OA 
have been proposed. The radiographic definition of OA relies pri- 
marily on the evaluation of both osteophytes and joint space nar- 
rowing (JSN), while the assessment of OA severity relies largely 
on JSN and subchondral bone lesions. Progression of JSN is the 
most commonly used criterion for the assessment of OA progres- 
sion and the complete loss of JSW characterized by bone on 
bone contact is a factor considered in the decision for joint re- 
placement. The growing number of publications on radiographic 
assessment of OA over the recent past years highlights a re- 
newed interest in the assessment of disease progression driven 
in particular by randomized controlled clinical trials (RCTs) for 
Disease Modifying OA Drugs (DMOADs). In the past, studies 
generally used standard plain radiographs (i.e., anteroposterior 
(AP) view of the pelvis for the hip and standing AP view of the 
femorotibial joint for the knee). In recent years, the precision and 
sensitivity of standard plain radiographs for detecting early OA 
and measuring disease progression has been questioned. In ad- 
dition, the demonstration of chondroprotection i DMOAD RCTs 
has demonstrated to be a significant challenge using radiogra- 
phy. This presentation will review the limitations of conventional 
radiography and the progress that has been made in the recent 
years. 
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MAGNETIC RESONANCE IMAGING: DISEASE 
MODIFYING OSTEOARTHRITIS DRUG CLINICAL TRIAL 
PERSPECTIVE 
JL Evelhoch 
More sensitive biomarkers of cartilage degradation are needed to 
facilitate development of disease modifying osteoarthritis drugs 
(DMOAD). Over the past decade, magnetic resonance imaging 
(MRI) techniques, with 3-dimensional imaging capability and high 
soft tissue contrast, have been developed for quantifying cartilage 
morphology throughout the knee. Quantitative cartilage morphol- 
ogy measurements by MRI correlate strongly with independent 
measurements made in specimens from cadavers and/or total 
knee arthroplasty. Longitudinal quantitative MRI studies of OA 
patients indicate that total cartilage volume decreases 4-6% per 
year, with twice that regionally. The variability (test-retest) of total 
cartilage volume in single center studies is 3-4% at 1.5 T(esla) 
and is reduced to 2-3% at 3 T. Thus, multi-center studies should 
be able to detect treatment effects on cartilage degradation in 6- 
12 months with a hundred subjects per arm. Due to the face va- 
lidity of MRI cartilage measurements, there is great interest within 
the drug development industry and regulatory bodies to evaluate 
the potential of quantitative MRI measurements of cartilage mor- 
phology as a surrogate endpoint. 
In addition to these morphometric measurements, several MRI 
methods have been developed to assess cartilage composition, 
including T2, TII~, dGEMRIC and sodium imaging. The T2 and 
T11~ methods rely on changes in these MR properties due to al- 
terations in the biophysical environment of water resulting from 
changes in the cartilage composition. The dGEMRIC (delayed 
Gadolinium Enhanced MRI of Cartilage) and sodium imaging 
methods take advantage of the negative charge of glycosamino- 
glycan (GAG, a principal component of aggrecan), which de- 
creases the amount of Gd(DTPA)2- (i.e., most widely used MRI 
contrast agents) and increases the amount of sodium that pen- 
etrates the cartilage. Since dGEMRIC uses the higher sensitiv- 
ity (and resulting spatial resolution) of proton MRI to image the 
contrast agent distribution, its use to non-invasively assess the 
GAG distribution is of particular interest. Aggrecan is lost in hu- 
man cartilage regions with no detectable collagen loss and de- 
grades before collagen during stimulated cartilage breakdown, 
so it may protect cartilage collagen from degradation. Thus, as 
suggested by the observation that in patients with hip dysplasia, 
the dGEMRIC index, but not JSW, correlates with pain and the 
severity of the dysplasia, dGEMRIC measurement of aggrecan 
depletion could provide an early indicator of OA progression or 
drug effect. Further evaluation of the performance of dGEMRIC 
and the other MR-based methods to assess cartilage composi- 
tion in the context of clinical trials is needed to determine their 
